Biotech stocks are experiencing a resurgence, driven in part by the announcement of Robert F. Kennedy Jr.’s appointment as head of the US Department of Health and Human Services. While some investors may be concerned about the impact of this change on the industry, others see opportunities for growth.
One stock that stands out is Halozyme Therapeutics (HALO), which has seen its shares surge after the company reiterated its 2024 outlook and raised its 2025 guidance. The biotech firm’s Enhanze technology delivers drugs under the skin via a subcutaneous injection, a technique behind some of the biggest cancer treatments.
Another stock making headlines is Exelixis (EXEI), which has focused on developing cancer treatments. Its sales for the fourth quarter were strong, with preliminary US sales reaching $1.81 billion. The company also guided to $1.95 billion to $2.05 billion in sales for 2025.
ADMA Biologics (ADMA) is also experiencing a rebound after its independent auditor unexpectedly resigned. However, shares have jumped almost 15% on Nov. 8 after the company reported adjusted earnings above expectations. The biotech firm’s human immune globulin products are intravenous infusions for people with immunodeficiencies.
Exelixis and Halozyme Therapeutics have strong Composite Ratings of 92 and 97, respectively, indicating their potential for long-term growth. While shares of ADMA Biologics remain below its 50-day moving average, the company’s Relative Strength Rating is high at 96, suggesting it could be a contender.
As investors look to the future, they may want to consider biotech stocks like these, which are poised to capitalize on emerging trends in healthcare and technology.
Source: https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run